

ACURA PHARMACEUTICALS, INC  
 Form 4  
 January 05, 2016

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**SKELLY WILLIAM G**

2. Issuer Name and Ticker or Trading Symbol  
**ACURA PHARMACEUTICALS, INC [ACUR]**

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
 01/04/2016

Director  10% Owner  
 Officer (give title below)  Other (specify below)

C/O ACURA PHARMACEUTICALS, INC., 616 N. NORTH COURT

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

PALATINE, IL 60067

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D) Code V Amount (D) Price			
Common Stock	01/04/2016		M <sup>(1)</sup>	8,247 A <u>(2)</u>	15,129 <sup>(3)</sup> <u>(4)</u>	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Restricted Stock Units <sup>(4)</sup>	<u>(2)</u>	01/04/2016		D		2,062	<u>(5)</u>	<u>(5)</u>	Common Stock	2,062
Restricted Stock Units <sup>(4)</sup>	<u>(2)</u>	01/04/2016		M		8,247	<u>(5)</u>	<u>(5)</u>	Common Stock	8,247
Restricted Stock Units	<u>(2)</u>	01/04/2016		A		22,026	<u>(7)</u>	<u>(7)</u>	Common Stock	22,026

## Reporting Owners

**Reporting Owner Name / Address**

**Relationships**

Director    10% Owner    Officer    Other

SKELLY WILLIAM G  
C/O ACURA PHARMACEUTICALS, INC.  
616 N. NORTH COURT  
PALATINE, IL 60067

X

## Signatures

/s/ William

Skelly

01/05/2016

      
\*\*Signature of  
Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Represents exchange of restricted stock units.

(2) Par value of \$.01 must be paid by Reporting Person (or withheld from cash distributions) upon exchange of Restricted Stock Units for cash or stock

(3) Does not include Restricted Stock Units.

(4) Reflects 1 for 5 Reverse Stock Split effective August 27, 2015.

(5) 25% of Restricted Stock Units vested on March 31, 2015, 25% vested on June 30, 2015; 25% vested on September 30, 2015 and 25% vested on December 31, 2015. Reporting Person elected to exchange 40% (2,062) of Restricted Stock Units for cash (less par value of \$.01 per share). Remaining Restricted Stock Units are being exchanged on a one for one basis for common stock, in each case upon payment of, or deduction of par value.

Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 4

(6) Represents closing price of Issuer's common stock on December 31, 2015.

25% of Restricted Stock Units vest on the last day of each of March, June, September and December 2016. Reporting Person may elect to

(7) exchange up to 40% of Restricted Stock Units for cash and the remaining Restricted Stock Units will be exchanged on a one for one basis for common stock, in each case upon payment of, or deduction of par value. Distributions in respect of vested Restricted Stock Units will be made on the first business day of January 2017.

(8) N/A

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.